Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2012

01-06-2012 | Mini Review

Glucose metabolism in patients with subclinical Cushing’s syndrome

Authors: Roberta Giordano, Federica Guaraldi, Rita Berardelli, Ioannis Karamouzis, Valentina D’Angelo, Elisa Marinazzo, Andreea Picu, Ezio Ghigo, Emanuela Arvat

Published in: Endocrine | Issue 3/2012

Login to get access

Abstract

This clinical review will summarize the available data regarding the effect of either physiological or increased glucocorticoid concentrations on glucose metabolism and insulin-sensitivity, in order to clarify the role, if any, of subclinical Cushing’s syndrome (SCS), a status of altered hypothalamic–pituitary–adrenal axis secretion in the absence of the classical signs or symptoms of overt cortisol excess, in patients with adrenal incidentalomas (AI) and diabetes mellitus type 2. Focusing on patients with SCS associated to AI, while there is convincing evidence in the literature that even a mild hyper cortisolemia is associated with alterations of glucose metabolism, evidence is insufficient to conclude that the simple correction of chronic, even mild, hypercortisolism can completely revert metabolic, mainly glycemic alterations. At the same time, considering the variability of the prevalence of Cushing’s syndrome in patients with diabetes mellitus type 2 reported in the literature, no agreement does exist whether screening for CS can be useful and recommended in those patients.
Literature
1.
M. Reincke, Subclinical Cushing’s syndrome. Endocrinol. Metab. Clin. North Am. 29, 47–56 (2000)CrossRef
2.
M. Terzolo, G. Reimondo, S. Bovio, A. Angeli, Subclinical Cushing’s syndrome. Pituitary 7, 217–223 (2004)PubMedCrossRef
3.
S. Tsagarakis, D. Vassiliadi, N. Thalassinos, Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J. Endocrinol. Invest. 29, 471–482 (2006)PubMed
4.
I. Chiodini, Diagnosis and treatment of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 96, 1223–1236 (2011)PubMedCrossRef
5.
L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)PubMedCrossRef
6.
J.W. Funder, Glucocorticoid and mineralcorticoid receptors: biology and clinical relevance. Annu. Rev. Med. 48, 231–240 (1997)PubMedCrossRef
7.
C.M. Bamberger, H.M. Schulte, G.P. Chrousos, Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17, 245–261 (1996)PubMed
8.
R.H. DeRijk, M. Schaaf, E.R. de Kloet, Glucocorticoid receptor variants: clinical implications. J. Steroid. Biochem. Mol. Biol. 81, 103–122 (2002)PubMedCrossRef
9.
J.R. Seckl, 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr. Opin. Pharmacol. 4, 597–602 (2004)PubMedCrossRef
10.
R.C. Andrews, B.R. Walker, Glucocorticoids and insulin resistance: old hormones, new targets. Clin. Sci. 96, 513–523 (1999)PubMedCrossRef
11.
D.H. van Raalte, D.M. Ouwens, M. Diamant, Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur. J. Clin. Invest. 38, 81–93 (2009)CrossRef
12.
M.F. Dallman, A.M. Strack, S.F. Akana, M.J. Bradbury, E.S. Hanson, K.A. Scribner, M. Smith, Feast and famine: critical role of glucocorticoids with insulin in daily energy fow. Front. Neuroendocrinol. 14, 303–347 (1993)PubMedCrossRef
13.
D. Qi, B. Rodrigues, Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am. J. Physiol. Endocrinol. Metab. 292, E654–E667 (2007)PubMedCrossRef
14.
T. Lemberger, B. Staels, R. Saladin, B. Desvergne, J. Auwerx, W. Wahli, Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J. Biol. Chem. 269, 24527–24530 (1994)PubMed
15.
R. Patel, M. Patel, R. Tsai, V. Lin, A.L. Bookout, Y. Zhang, L. Magomedova, T. Li, J.F. Chan, C. Budd, D.J. Mangelsdorf, C.L. Cummins, LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J. Clin. Invest. 121, 431–441 (2011)PubMedCrossRef
16.
F. Delaunay, A. Khan, A. Cintra, B. Davani, Z.C. Ling, A. Andersson, C.G. Ostenson, J. Gustafsson, S. Efendic, S. Okret, Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 100, 2094–2098 (1997)PubMedCrossRef
17.
D.H. van Raalte, M. Brands, N.J. van der Zijl, M.H. Muskiet, P.J.W. Pouwels, M.T. Ackermans, H.P. Sauerwein, M.J. Serlie, M. Diamant, Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 54, 2103–2112 (2011)PubMedCrossRef
18.
M. Stubbs, D.A. York, Central glucocorticoid regulation of parasympathetic drive to pancreatic B-cells in the obese fa/fa rat. Int. J. Obes. 15, 547–553 (1991)PubMed
19.
R. Pivonello, M. De Leo, P. Vitale, A. Cozzolino, C. Simeoli, M.C. De Martino, G. Lombardi, A. Colao, Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 77–81 (2010)PubMedCrossRef
20.
G. Mazziotti, C. Gazzaruso, A. Giustina, Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 17, 144–149 (2011)CrossRef
21.
G.T. Griffing, Editorial A-I-D-S: the new endocrine epidemic. J. Clin. Endocrinol. Metab. 79, 1530–1531 (1994)PubMedCrossRef
22.
R.T. Kloos, M.D. Gross, I.R. Francis, M. Korobkin, B. Shapiro, Incidentally discovered adrenal masses. Endocr. Rev. 16, 460–484 (1995)PubMed
23.
R.M. Chidiac, D.C. Aron, Incidentaloma a disease of modern technology. Endocrinol. Metab. Clin. North Am. 26, 233–253 (1997)PubMedCrossRef
24.
M.M. Grumbach, B.M.K. Biller, G.D. Braunstein, K.K. Campbell, J.A. Carney, P.A. Godley, E.L. Harris, J.K.T. Lee, Y.C. Oertel, M.C. Posner, J.A. Schlechte, H.S. Wieand, Management of the clinically inapparent adrenal mass (‘Incidentaloma’). Ann. Intern. Med. 138, 424–429 (2003)PubMed
25.
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, S.R. Bornstein, The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25, 309–340 (2004)PubMedCrossRef
26.
W.F. Young Jr, Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 356, 601–610 (2007)PubMedCrossRef
27.
A. Tabarin, S. Bardet, J. Bertherat, B. Dupas, O. Chabre, E. Hamoir, F. Laurent, F. Tenenbaum, M. Cazalda, H. Lefebvre, N. Valli, V. Rohmer, Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus. Ann. Endocrinol. 69, 487–500 (2008)CrossRef
28.
L.K. Nieman, Approach to the patient with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 95, 4106–4113 (2010)PubMedCrossRef
29.
M. Terzolo, A. Stigliano, I. Chiodini, P. Loli, L. Furlani, G. Arnaldi, G. Reimondo, A. Pia, V. Toscano, M. Zini, G. Borretta, E. Papini, P. Garofalo, B. Allolio, B. Dupas, F. Mantero, A. Tabarin, Italian Association of Clinical Endocrinologists. AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 164, 851–870 (2011)PubMedCrossRef
30.
R. Rossi, L. Tauchmanova, A. Luciano, M. Di Martino, C. Battista, L. Del Viscovo, V. Nuzzo, G. Lombardi, Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85, 1440–1448 (2000)PubMedCrossRef
31.
F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Masini, A. Alì, M. Giovagnetti, G. Opocher, A. Angeli, A survey on adrenal incidentaloma in Italy. J. Clin. Endocrinol. Metab. 85, 637–644 (2000)PubMedCrossRef
32.
M. Terzolo, A. Pia, A. Alì, G. Osella, G. Reimondo, S. Bovio, F. Daffara, M. Procopio, P. Paccotti, G. Borretta, A. Angeli, Adrenal incidentaloma: a new cause of the metabolic syndrome? J. Clin. Endocrinol. Metab. 87, 998–1003 (2002)PubMedCrossRef
33.
L. Tauchmanovà, R. Rossi, B. Biondi, M. Pulcrano, V. Nuzzo, E.A. Palmieri, S. Fazio, G. Lombardi, Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J. Clin. Endocrinol. Metab. 87, 4872–4878 (2002)PubMedCrossRef
34.
M. Terzolo, S. Bovio, G. Reimondo, A. Pia, G. Osella, G. Borretta, A. Angeli, Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol. Metab. Clin. North. Am. 34, 423–439 (2005)PubMedCrossRef
35.
G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)PubMedCrossRef
36.
R. Emral, A.R. Uysal, M. Asik, S. Gullu, D. Corapcioglu, V. Tonyukuk, G. Erdogan, Prevalence of subclinical Cushing’s syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr. J. 50, 399–408 (2003)PubMedCrossRef
37.
V. Morelli, B. Masserini, A.S. Salcuni, C. Eller-Vainicher, C. Savoca, R. Viti, F. Coletti, G. Guglielmi, C. Battista, L. Iorio, P. Beck-Peccoz, B. Ambrosi, M. Arosio, A. Scillitani, I. Chiodini, Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin. Endocrinol. 73, 161–166 (2010)
38.
G.P. Bernini, A. Moretti, C. Oriandini, M. Bardini, C. Taurino, A. Salvetti, Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br. J. Cancer 92, 1104–1109 (2005)PubMedCrossRef
39.
M. Terzolo, S. Bovio, A. Pia, P.A. Conton, G. Reimondo, C. Dall’Asta, D. Bemporad, A. Angeli, G. Opocher, M. Mannelli, B. Ambrosi, F. Mantero, Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur. J. Endocrinol. 153, 307–315 (2005)PubMedCrossRef
40.
M. Sereg, A. Szappanos, J. Toke, K. Karlinger, K. Feldman, E. Kaszper, I. Varga, E. Gláz, K. Rácz, M. Tóth, Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur. J. Endocrinol. 160, 647–655 (2009)PubMedCrossRef
41.
E. Vassilatou, A. Vryonidou, S. Michalopoulou, J. Manolis, J. Caratzas, C. Phenekos, I. Tzavara, Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin. Endocrinol. 70, 674–679 (2009)CrossRef
42.
R. Giordano, E. Marinazzo, R. Berardelli, A. Picu, M. Maccario, E. Ghigo, E. Arvat, Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur. J. Endocrinol. 162, 779–785 (2010)PubMedCrossRef
43.
A. Comlekci, S. Yener, S. Ertilav, M. Secil, B. Akinci, T. Demir, L. Kebapcilar, F. Bayraktar, S. Yesil, S. Eraslan, Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 37, 40–46 (2010)PubMedCrossRef
44.
M. Reincke, M. Fassnacht, S. Vath, P. Mora, B. Allolio, Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr. Res. 22, 757–761 (1996)PubMed
45.
G. Muscogiuri, G.P. Sorice, A. Prioletta, T. Mezza, C. Cipolla, E. Salomone, A. Giaccari, A. Pontecorvi, C.S. Della, The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin. Endocrinol. 74, 300–305 (2011)CrossRef
46.
S. Midorikawa, H. Sanada, S. Hashimoto, T. Suzuki, T. Watanabe, The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin. Endocrinol. 54, 797–804 (2001)CrossRef
47.
G. Bernini, A. Moretti, P. Iacconi, P. Miccoli, R. Nami, B. Lucani, A. Salvetti, Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur. J. Endocrinol. 148, 213–219 (2003)PubMedCrossRef
48.
Y. Erbil, E. Ademoglu, N. Ozbey, U. Barbaros, B.T. Yanik, A. Salmaslioglu, A. Bozbora, S. Ozarmagan, Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J. Surg. 30, 1665–1671 (2006)PubMedCrossRef
49.
I.C. Mitchell, R.J. Auchus, K. Juneja, A.Y. Chang, S.A. Holt, W.H. Snyder, F.E. Nwariaku, “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 142, 900–905 (2007)PubMedCrossRef
50.
M. Tsuiki, A. Tanabe, S. Takagi, M. Naruse, K. Takano, Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocr. J. 55, 737–745 (2008)PubMedCrossRef
51.
A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249, 388–391 (2009)PubMedCrossRef
52.
I. Chiodini, V. Morelli, A.S. Salcuni, C. Eller-Vainicher, M. Torlontano, F. Coletti, L. Iorio, A. Cuttitta, A. Ambrosio, L. Vicentini, F. Pellegrini, M. Copetti, P. Beck-Peccoz, M. Arosio, B. Ambrosi, V. Trischitta, A. Scillitani, Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J. Clin. Endocrinol. Metab. 95, 2736–2745 (2010)PubMedCrossRef
53.
M.A. Zeiger, G.B. Thompson, Q.Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj, E. Fishman, J. Kharlip, The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15, 1–20 (2009)PubMed
54.
D.A. Vassiliadi, G. Ntali, T. Stratigou, M. Adali, S. Tsagarakis, Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine 40, 437–444 (2011)PubMedCrossRef
55.
O.G. Cameron, B. Thomas, D. Tiongco, M. Hariharan, J.F. Greden, Hypercortisolism in diabetes mellitus. Diabetes Care 10, 662–664 (1987)PubMed
56.
C. Tsigos, R.J. Young, A. White, Diabetic neuropathy is associated with increased activity of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 76, 554–558 (1993)PubMedCrossRef
57.
M.S. Roy, A. Roy, W.T. Gallucci, B. Collier, K. Young, T.C. Kamilaris, G.P. Chrousos, The ovine corticotropin-releasing hormone-stimulation test in type I diabetic patients and controls: suggestion of mild chronic hypercortisolism. Metabolism 42, 696–700 (1993)PubMedCrossRef
58.
G. Leibowitz, A. Tsur, S.D. Chayen, M. Salameh, I. Raz, E. Cerasi, D.J. Gross, Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin. Endocrinol. 44, 717–722 (1996)CrossRef
59.
L.N. Contreras, E. Cardoso, M.P. Lozano, J. Pozzo, P. Pagano, H. Claus-Hermbeg, Detection of preclinical Cushing’s syndrome in overweight type 2 diabetic patients. Medicina (B Aires) 60, 326–330 (2000)
60.
B. Catargi, V. Rigalleau, A. Poussin, N. Ronci-Chaix, V. Bex, V. Vergnot, H. Gin, P. Roger, A. Tabarin, Occult Cushing’s syndrome in type-2 diabetes. J. Clin. Endocrinol. Metab. 88, 5808–5813 (2003)PubMedCrossRef
61.
I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, G. Adda, V. Trischitta, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur. J. Endocrinol. 153, 837–844 (2005)PubMedCrossRef
62.
H. Liu, D.M. Bravata, J. Cabaccan, H. Raff, E. Ryzen, Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin. Endocrinol. 63, 642–649 (2005)CrossRef
63.
G. Reimondo, A. Pia, B. Allasino, F. Tassone, S. Bovio, G. Borretta, A. Angeli, M. Terzolo, Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin. Endocrinol. 67, 225–229 (2007)CrossRef
64.
T. Taniguchi, A. Hamasaki, M. Okamoto, Subclinical hypercortisolism in hospitalized patients with type 2 diabetes mellitus. Endocr. J. 55, 429–432 (2008)PubMedCrossRef
65.
S. Newsome, K. Chen, J. Hoang, J.D. Wilson, J.M. Potter, P.E. Hickman, Cushing’s syndrome in a clinic population with diabetes. Intern. Med. J. 38, 178–182 (2008)PubMedCrossRef
66.
L. Gagliardi, I.M. Chapman, P. O’ Loughlin, D.J. Torpy, Screening for subclinical Cushing’s syndrome in type 2 diabetes mellitus: low false-positive rates with nocturnal salivary cortisol. Horm. Metab. Res. 42, 280–284 (2010)PubMedCrossRef
67.
K. Mullan, N. Black, A. Thiraviaraj, P.M. Bell, C. Burgess, S.J. Hunter, D.R. McCance, H. Leslie, B. Sheridan, A.B. Atkinson, Is there a value in routine screening for Cushing’s syndrome in patients with diabetes? J. Clin. Endocrinol. Metab. 95, 2262–2265 (2010)PubMedCrossRef
Metadata
Title
Glucose metabolism in patients with subclinical Cushing’s syndrome
Authors
Roberta Giordano
Federica Guaraldi
Rita Berardelli
Ioannis Karamouzis
Valentina D’Angelo
Elisa Marinazzo
Andreea Picu
Ezio Ghigo
Emanuela Arvat
Publication date
01-06-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9628-9

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue

Original Article

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

Review

Obesidomics: contribution of adipose tissue secretome analysis to obesity research

Review

Diagnostics and treatment of the diabetic foot

Original Article

Positive correlation between type 1 and 2 iodothyronine deiodinases activities in human goiters

Original Article

Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas

Original Article

Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits